ERYTECH Pharma S.A. (ERYP)

$1.28

-0.10 (-7.25%)
Rating:
Recommendation:
Buy
Symbol ERYP
Price $1.28
Beta 1.562
Volume Avg. 0.05M
Market Cap 39.701M
Shares () -
52 Week Range 0.3-2.18
1y Target Est -
DCF Unlevered ERYP DCF ->
DCF Levered ERYP LDCF ->
ROE -67.94% Strong Sell
ROA -27.85% Sell
Operating Margin -
Debt / Equity 194.10% Buy
P/E -
P/B 1.50 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ERYP news


Mr. Gil Beyen BVBA
Healthcare
Biotechnology
NASDAQ Global Select

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.